Citius Oncology, Inc. CTOR 深 沪
等待开盘 08-18 09:30:00 美东时间
0.74
-0.170
-18.66%
华盛通- 最 高0.7816
- 今 开0.735
- 成交量 27.50万股
- 最 低 0.7003
- 昨 收 0.9098
- 总市值 6880.61万
- 52周最高 2.25
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 0.4912
- 委 比 -36.99%
- 总股本 9298.12万
- 历史最高 49.00
- 量 比 2.58
- 振 幅 8.94%
- 历史最低 0.00
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of HIVE Digital Technologies Ltd (NASDAQ:HIVE) rose sharply in pre-market trading. HIVE’s subsidiary BUZZ High Performance Computing Inc. announced that it has signed a five-year GPU cloud services agreement with an investment-grade enterprise customer. The company, on Friday, posted first-qu...
08-17 16:54
Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494 million which missed the analyst consensus estimate of $2.500 million by 40.24 perce...
08-15 04:58
Citius Oncology Reports 78% QoQ Growth In New Institutional Accounts Ordering LYMPHIR; Near‑Universal Payer Coverage Expands Market Access With Initial CTCL Market Exceeding $400M
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., Aug. 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. (...
08-05 21:22
Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Ph...
07-21 21:19
Citius Oncology Presents Phase 1 Clinical Data Of LYMPHIR In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies At American Society Of Clinical Oncology Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today highlighted
06-01 19:21
Citius Oncology Provides Commercial Update On U.S. Launch Of LYMPHIR For Treatment Of CTCL, Highlighting Continued Adoption And Advancing Investigator-Led Clinical Studies
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integrationCRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius
03-31 21:14
美股夜盘 | Health In Tech, Inc. Class A涨50.00%，ZenaTech, Inc.涨19.30%
Health In Tech, Inc. Class A涨50.00%；ZenaTech, Inc.涨19.30%；金山云涨15.24%
03-18 15:03
Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response (PR)LYMPHIR was
03-04 22:18
Earnings Breakdown: Citius Oncology Q1
Citius Oncology (NASDAQ:CTOR) reported its Q1 earnings results on Friday, Febru...
02-13 21:24
Citius Oncology Q1 Earnings Summary & Key Takeaways
The earnings results for Citius Oncology (NASDAQ:CTOR) for Q1 were made public ...
02-13 21:12
